These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23958309)

  • 1. Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment.
    Wood SL; Westbrook JA; Brown JE
    Cancer Treat Rev; 2014 Feb; 40(1):139-52. PubMed ID: 23958309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer.
    Brockton NT; Gill SJ; Laborge SL; Paterson AH; Cook LS; Vogel HJ; Shemanko CS; Hanley DA; Magliocco AM; Friedenreich CM
    BMC Cancer; 2015 Jul; 15():512. PubMed ID: 26156521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal-related adverse events during bone metastasis of breast cancer: current status.
    Yang M; Liu C; Yu X
    Discov Med; 2019 May; 27(149):211-220. PubMed ID: 31361984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer bone metastases: pathogenesis and therapeutic targets.
    Brook N; Brook E; Dharmarajan A; Dass CR; Chan A
    Int J Biochem Cell Biol; 2018 Mar; 96():63-78. PubMed ID: 29309917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of bone metastases of breast cancer.
    Suva LJ; Griffin RJ; Makhoul I
    Endocr Relat Cancer; 2009 Sep; 16(3):703-13. PubMed ID: 19443538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Mechanisms of Bone Metastasis.
    Weidle UH; Birzele F; Kollmorgen G; Rüger R
    Cancer Genomics Proteomics; 2016; 13(1):1-12. PubMed ID: 26708594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular signature of breast cancer metastasis to bone.
    Bahrami T; Mokmeli S; Hossieni H; Pourpaknia R; Makani Z; Salmaninejad A; Estiar MA; Hossieni A; Farshbaf A
    Anticancer Drugs; 2016 Oct; 27(9):824-31. PubMed ID: 27384592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise of bone cancer proteomics.
    Byrum S; Montgomery CO; Nicholas RW; Suva LJ
    Ann N Y Acad Sci; 2010 Mar; 1192():222-9. PubMed ID: 20392240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From latency to overt bone metastasis in breast cancer: potential for treatment and prevention.
    Salvador F; Llorente A; Gomis RR
    J Pathol; 2019 Sep; 249(1):6-18. PubMed ID: 31095738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
    Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
    BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating distant metastases in breast cancer: from biology to outcomes.
    Rabbani SA; Mazar AP
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):663-74. PubMed ID: 17823779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
    Brennan DJ; Kelly C; Rexhepaj E; Dervan PA; Duffy MJ; Gallagher WM
    Cancer Genomics Proteomics; 2007; 4(3):121-34. PubMed ID: 17878516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
    Iglesias-Gato D; Thysell E; Tyanova S; Crnalic S; Santos A; Lima TS; Geiger T; Cox J; Widmark A; Bergh A; Mann M; Flores-Morales A; Wikström P
    Clin Cancer Res; 2018 Nov; 24(21):5433-5444. PubMed ID: 30042207
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone Metastasis of Breast Cancer.
    Tahara RK; Brewer TM; Theriault RL; Ueno NT
    Adv Exp Med Biol; 2019; 1152():105-129. PubMed ID: 31456182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.
    Buijs JT; Kuijpers CC; van der Pluijm G
    Curr Pharm Des; 2010; 16(27):3015-27. PubMed ID: 20722621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic approaches for protecting bone health in patients with breast cancer.
    Lüftner D; Niepel D; Steger GG
    Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.